http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-102018077083-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_054408286b7975436cc2e1f4b7917dcc http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_44c2e1aaf228297cd59cddcd774d2147 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-282 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-24 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-282 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-24 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-282 |
| filingDate | 2018-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76c583c36e23db86e2a2bef1292af37e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c90c34c52dbc9c9f892dc9946387e985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1fd17c763dba088c107156a07258723 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_990ddfe5eee4d0c3f22ab16b29c8d1ce http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7685e73f6b4c808944501cbe24f52193 |
| publicationDate | 2020-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-102018077083-A2 |
| titleOfInvention | platinum-based antitumor chemotherapy analogous to nedaplatin |
| abstract | platinum-based anti-tumor chemotherapy analogous to nedaplatin. the present invention is a platinum-based antineoplastic chemotherapy (ii), with a structure similar to nedaplatin (commercially available compound). the referred invention presents itself as a technological innovation, from a synthetic point of view and in terms of the field of its application (cancer treatment). the compound, presented here as an invention, was characterized by thermal analysis (tga) and spectroscopic techniques, among which we can mention: electronic absorption (uv-vis), infrared spectroscopy (ftir), 1h, 13c nuclear magnetic resonance (rmn) and 195pt, including for the latter case, 2d rmn techniques (hmbc and hsqc). the antitumor activity (in vitro) of said compound was evaluated against all human tumor cell lines: (i) hep-2 (laryngeal carcinoma), (ii) nci-h292 (mucoepidermoid carcinoma of the lung), (iii ) mcf-7 (human breast cancer) and (iv) hl-60 (acute promyelocytic leukemia); obtaining tumor inhibition percentages of 77; 82; 73 and 90%, respectively. referring to in vivo assays, mus musculus mice (Swiss lineage) were used as an animal model, for which (treated group) ehrlich carcinoma-type tumor cells (106 cells / ml) were inoculated in the sub-axillary region ), thus obtaining, at the end of treatment for a preferential dose of 1 mg / kg, a percentage of inhibition of 76%. it is worth mentioning that all animal experimentation and procedures were approved by the ufpe ethics and animal use committee, under license No. 23076.030363 / 2017-48. |
| priorityDate | 2018-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 37.